Efficacy and Safety Analysis of ICIs Plus Angiogenesis Inhibitors for Treatment of Advanced NSCLC in Elderly Patients

Immune checkpoint inhibitors(ICIs) combined with angiogenesis inhibitors may is synergistic in elderly patients with advanced non-small cell lung cancer(NSCLC), however its true efficacy is still unclear. The investigators retrospectively compared clinical efficacy and safety of driver-negative elderly patients with advanced NSCLC treated with ICIs with(or without)angiogenesis inhibitors in the Cancer Center of the Affiliated Suzhou Hospital of Nanjing Medical University.

Inclusion Criteria:Age ≥65 years old.Stage IV according to the AJCC Cancer grading manual (8th edition).Histologically confirmed NSCLC.No driver mutations.Received at least 2 courses of immunotherapy.Expected survival time > 3 months.No concurrent malignancy.Not participating in a clinical trial.The functions of important organs were basically normal.Sign informed consent.